Pharma-Bio Serv, Inc. PBSV
OTC PK
| 07/31/2026 | 04/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -13.57% | 17.77% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -13.57% | 17.77% | |||
| Cost of Revenue | -8.70% | 14.52% | |||
| Gross Profit | -23.31% | 24.86% | |||
| SG&A Expenses | 0.81% | -7.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.88% | 7.06% | |||
| Operating Income | -149.62% | 253.12% | |||
| Income Before Tax | -104.64% | 555.89% | |||
| Income Tax Expenses | -51.56% | 77.78% | |||
| Earnings from Continuing Operations | -106.09% | 608.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -106.09% | 608.21% | |||
| EBIT | -149.62% | 253.12% | |||
| EBITDA | -136.70% | 298.62% | |||
| EPS Basic | -105.88% | 628.57% | |||
| Normalized Basic EPS | -104.62% | 550.00% | |||
| EPS Diluted | -110.00% | 900.00% | |||
| Normalized Diluted EPS | -104.62% | 550.00% | |||
| Average Basic Shares Outstanding | 0.00% | -0.02% | |||
| Average Diluted Shares Outstanding | -0.01% | -0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||